The utility of FDG-PET in the preoperative staging of esophageal cancer

Diseases of the Esophagus

Volumn 21, Issue 5, 2008, Pages 389-394

  Gananadha, S ^a   Hazebroek, E J ^a   Leibman, S ^a   Berry, H ^a   Osgood, L ^a   Shon, I Ho ^a,b   Pavlakis, N ^a   Marx, G ^a   Smith, Garett S ^a  

^a ROYAL NORTH SHORE HOSPITAL   (Australia)

^b LIVERPOOL HOSPITAL   (Australia)

Author keywords

Esophageal cancer; Esophago gastricjunction cancer; Positronemission tomography

Indexed keywords

ANTINEOPLASTIC AGENT; FLUORODEOXYGLUCOSE; FUROSEMIDE; PLATINUM DERIVATIVE;

ADULT; AGED; ARTICLE; AUSTRALIA; BARRETT ESOPHAGUS; CANCER COMBINATION CHEMOTHERAPY; CANCER STAGING; CLINICAL STUDY; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; ENDOSCOPIC ECHOGRAPHY; ESOPHAGUS CANCER; ESOPHAGUS RESECTION; FEMALE; GASTROINTESTINAL DYSPLASIA; GASTROINTESTINAL STROMAL TUMOR; HUMAN; LOWER ESOPHAGUS SPHINCTER; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD; PATIENT REFERRAL; POSITRON EMISSION TOMOGRAPHY; PREOPERATIVE EVALUATION; PRIORITY JOURNAL; PROSPECTIVE STUDY; STOMACH CANCER; SURGEON; TEACHING HOSPITAL;

ADULT; AGED; AGED, 80 AND OVER; COHORT STUDIES; ESOPHAGEAL NEOPLASMS; ESOPHAGECTOMY; ESOPHAGOGASTRIC JUNCTION; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; KAPLAN-MEIERS ESTIMATE; MALE; MIDDLE AGED; NEOPLASM INVASIVENESS; NEOPLASM STAGING; POSITRON-EMISSION TOMOGRAPHY; PREOPERATIVE CARE; PROSPECTIVE STUDIES; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY; SURVIVAL ANALYSIS; TOMOGRAPHY, X-RAY COMPUTED; TREATMENT OUTCOME;

EID: 48649083803     PISSN: 11208694     EISSN: 14422050     Source Type: Journal    
DOI: 10.1111/j.1442-2050.2007.00802.x     Document Type: Article

References (19)

1. Enzinger P C, Mayer R J. Esophageal cancer. N Eng J Med 2003; 349: 2241-52.
2. Burmeister B H, Smithers B M, Gebski V et al. Trans-Tasman Radiation Oncology Group. Australasian Gastro-Intestinal Trials Group. Surgery alone versus chemoradiotherapy followed by surgery for resectable cancer of the oesophagus: A randomised controlled phase III trial. Lancet Oncol 2005; 6: 659-68.
3. Blazeby J M, Farndon J R, Donovan J, Alderson D. A prospective longitudinal study examining the quality of life of patients with oesophageal carcinoma. Cancer 2000; 88: 1781-7.
4. Zhang X, Watson D I, Jamieson G G, Lally C, Bessell J R, Devitt P G. Outcome of esophagectomy for adenocarcinoma of the oesophagus and oesophagogastric junction. ANZ J Surg 2005; 75: 513-9.
5. Mariette C, Finzi L, Fabre S, Balon J M, Van Seuningen I, Triboulet J P. Factors predictive of complete resection of operable esophageal cancer: a prospective study. Ann Thorac Surg 2003; 75: 1720-6.
6. Urschel J D, Vasan H. A meta-analysis of randomized controlled trials that compared neoadjuvant chemoradiation and surgery to surgery alone for resectable esophageal cancer. Am J Surg 2003; 185: 538-43.
7. Slater M S, Holland J, Faigel D O, Sheppard B C, Deveney C W. Does neoadjuvant chemoradiation downstage esophageal carcinoma? Am J Surg 2001; 181: 440-4.
8. Meneu-Diaz J C, Blazquez L A, Vicente E et al. The role of multimodality therapy for respectable esophageal cancer. Am J Surg 2000; 179: 308-13.
9. Yasuda S, Raja S, Hubner K F. Application of whole-body positron emission tomography in the imaging of esophageal cancer: Report of a case. Surg Today 1995; 25: 261-4.
10. Kato H, Miyazaki T, Nakajima M et al. The incremental effect of positron emission tomography on diagnostic accuracy in the initial staging of esophageal carcinoma. Cancer 2005; 103: 148-56.
11. Van Westreenen H L, Heeren P A, van Dullemen H M et al. Positron emission tomography with F-18-fluorodeoxyglucose in a combined staging strategy of esophageal cancer prevents unnecessary surgical explorations. J Gastrointest Surg 2005; 9: 54-61.
12. Kneist W, Schreckenberger M, Bartenstein P, Menzel C, Oberholzer K, Junginger T. Prospective evaluation of positron emission tomography in the preoperative staging of esophageal carcinoma. Arch Surg 2004; 139: 1043-9.
13. Van Westreenen H L, Heeren P A, Jager P L, van Dullemen H M, Groen H, Plukker J T. Pitfalls of positive findings in staging esophageal cancer with F-18-fluorodeoxyglucose positron emission tomography. Ann Surg Oncol 2003; 10: 1100-5.
14. Meyers B F, Downey R J, Decker P A et al. American College of Surgeons Oncology Group Z0060. The utility of positron emission tomography in staging of potentially operable carcinoma of the thoracic esophagus: results of the American College of Surgeons Oncology Group Z0060 trial. J Cardiothorac Surg 2007; 133: 738-45.
15. Kole A C, Plukker J T, Nieweg O E, Vaalburg W. Positron emission tomography for staging of oesophageal and gastroesophageal malignancy. Br J Cancer 1998; 78: 521-7.
16. Luketich J D, Schauer P R, Meltzer C C et al. Role of positron emission tomography in staging esophageal cancer. Ann Thorac Surg 1997; 64: 765-9.
17. Meltzer C C, Luketich J D, Friedman D et al. Whole-body FDG positron emission tomographic imaging for staging esophageal cancer comparison with computed tomography. Clin Nucl Med 2000; 25: 882-7.
18. Flamen P, Lerut A, Van Cutsem E et al. Utility of positron emission tomography for the staging of patients with potentially operable esophageal carcinoma. J Clin Oncol 2000; 18: 3202-10.
19. Van Westreenen H L, Westerterp M, Bossuyt P M et al. Systematic review of the staging performance of 18F-fluorodeoxyglucose positron emission tomography in esophageal cancer. J Clin Oncol 2004; 22: 3805-12.